Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

How does the Breast DCIS Score® test compare?

The Breast DCIS Score test

Icon VS

traditional assessment methods

The Breast DCIS Score report includes information that goes beyond standard clinical pathologic factors, such as1-3:

  • An individualized prediction of the 10-year risk of any local recurrence (DCIS or invasive carcinoma) or an invasive local recurrence
  • An established baseline for consideration of absolute benefit from radiation therapy (XRT)
  • Quantitative ER and PR single gene expression values

Genomic testing

Icon vs

genetic testing

Genetic tests help people understand their risk for getting cancer. Genomic tests help people who have been diagnosed with cancer plan their care. The Breast DCIS Score test examines 12 cancer-related genes in a patient’s tumor. The activity of these genes influences the behavior of the tumor, including how likely it is to grow and spread. The Breast DCIS Score test looks at these genes to help you and your patient make decisions about appropriate care.

Breast DCIS Score test                           

Icon vs

Breast Recurrence Score® test

The Breast DCIS Score test is specifically for patients with ductal carcinoma in situ (DCIS) treated by local excision. The Oncotype DX Breast Recurrence Score® test is a similar test for patients with early-stage and ER-positive invasive breast cancer.

 

Learn about the Breast Recurrence Score Test

Icon doctor

Use our online physician portal

Order tests, access results, receive updates, and more in one place.

Sign up now